The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region Significantly enhances Hansa's financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval SERB has a substantial...
Hence then, the article about hansa biopharma enters into 115 million licensing agreement with serb pharmaceuticals for idefirix in europe and mena was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA )
Also on site :
- Ukraine-Russia war latest: Xi reportedly told Trump that Putin might ‘regret’ invading Ukraine
- With Just Two Looks, Taylor Russell Is Already In the Running for Best-Dressed at Cannes
- Un estudio señala que las demoras en Lima durante las elecciones no habrían afectado el resultado en Perú